{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:25:08Z","timestamp":1787034308619,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cervical cancer is one of the leading causes of cancer-related mortality among women worldwide. While immune checkpoint inhibitors combined with bevacizumab and chemotherapy are emerging as the standard first-line therapy for recurrent or metastatic (R\/M) cervical cancer, substantial unmet needs remain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>ASTRUM-CC01 (NCT05444374) is a multicenter, single-arm, phase II trial. Eligible patients were aged 18\u201375 and had no prior systemic treatment. Patients received 4\u20136 cycles of serplulimab and bevacizumab combined with cisplatin and paclitaxel, followed by maintenance serplulimab and bevacizumab. The primary endpoint was objective response rate (ORR); secondary endpoints included progression-free survival (PFS), overall survival (OS), duration of response (DoR), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 48 patients were enrolled; 43 were evaluable for efficacy. The ORR was 75.00% (95% CI, 60.40-86.36), and the disease control rate (DCR) was 89.58% (95% CI, 77.34-96.53) in the overall population. The median PFS was 21.23 months (95% CI: 14.43-NR); OS data were immature, with an estimated 12-month OS rate of 83.97% (95% CI: 73.66-95.72). Subgroup analysis indicated that high baseline clinical stage at initial diagnosis was a risk factor for PFS (HR\u00a0=\u00a03.01,\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u00a00.023); other baseline characteristics, including PD-L1 expression levels and the location of recurrence, did not significantly correlate with survival. No new safety signals were observed. Grade \u2265r adverse events occurred in 21 patients (43.75%), including fistula events in 5 patients (10.42%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>First-line treatment with serplulimab in combination with bevacizumab and chemotherapy demonstrated promising antitumor activity and acceptable safety in R\/M cervical cancer. These findings support further evaluation in phase III trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1923961","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:36:22Z","timestamp":1787031382000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serplulimab combined with bevacizumab and chemotherapy as first-line treatment for recurrent or metastatic cervical cancer (ASTRUM-CC01): a phase II trial"],"prefix":"10.3389","volume":"17","author":[{"given":"Hong","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Gynecologic Oncology, Sichuan Cancer Hospital and Institute","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dengfeng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Sichuan Cancer Hospital and Institute","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Hunan Cancer Hospital","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Liaoning Cancer Hospital and Institute","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumin","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Linyi Cancer Hospital","place":["Linyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ge","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Harbin Medical University Cancer Hospital","place":["Harbin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guonan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecologic Oncology, Sichuan Cancer Hospital and Institute","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2021.1879646","article-title":"Optimal treatment in locally advanced cervical cancer","volume":"21","author":"Gennigens","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2015.03.235","article-title":"Curative pelvic exenteration for recurrent cervical carcinoma in the era of concurrent chemotherapy and radiation therapy. A systematic review","volume":"41","author":"Sardain","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/igc.0000000000001216","article-title":"The european society of gynaecological oncology\/european society for radiotherapy and oncology\/european society of pathology guidelines for the management of patients with cervical cancer","volume":"28","author":"Cibula","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2017.12.002","article-title":"Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics","volume":"52","author":"Hegde","year":"2018","journal-title":"Semin Cancer Biol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5500","DOI":"10.1136\/ijgc-2023-esgo.886","article-title":"KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00914","article-title":"First-line pembrolizumab + Chemotherapy versus placebo + Chemotherapy for persistent, recurrent, or metastatic cervical cancer: final overall survival results of KEYNOTE-826","volume":"41","author":"Monk","year":"2023","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.16464","article-title":"Effect of first-line serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial","volume":"328","author":"Cheng","year":"2022","journal-title":"JAMA"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02179-2","article-title":"First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial","volume":"29","author":"Song","year":"2023","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ccell.2023.12.004","article-title":"A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)","volume":"42","author":"Zhou","year":"2024","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1142256","DOI":"10.3389\/fimmu.2023.1142256","article-title":"Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study","volume":"14","author":"An","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2025.36.e110","article-title":"Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis","volume":"36","author":"Kim","year":"2025","journal-title":"J Gynecol Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2419838","article-title":"Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies","volume":"16","author":"Zhang","year":"2024","journal-title":"MAbs"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065x.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.5367","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: A systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2026.37.e13","article-title":"The activity of immune checkpoint inhibitors in patients with recurrent cervical cancer developed in previously irradiated field: clinical and immunohistochemical investigations","volume":"37","author":"Mabuchi","year":"2026","journal-title":"J Gynecol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0000451484.02983.78","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-012-9913-3","article-title":"Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients","volume":"38","author":"Borofsky","year":"2013","journal-title":"Abdom Imaging"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2011.12.030","article-title":"Bevacizumab-associated fistula formation in postoperative colorectal cancer patients","volume":"214","author":"Ganapathi","year":"2012","journal-title":"J Am Coll Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/ijgo.15609","article-title":"Bevacizumab is associated with a higher gastrointestinal\/genitourinary fistula or perforation risk in cervical cancer patients undergoing pelvic radiotherapy","volume":"167","author":"Yang","year":"2024","journal-title":"Int J Gynaecol Obstet"},{"key":"B26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/ijgc-2020-002031","article-title":"Use of bevacizumab before or after radiotherapy increases the risk of fistula formation in patients with cervical cancer","volume":"31","author":"Kim","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-025-02407-x","article-title":"Multimodal chemoradiotherapy including interstitial brachytherapy enhances outcomes in FIGO stage IVA cervical cancer: a focus on tumor control and quality of life","volume":"201","author":"Neu","year":"2025","journal-title":"Strahlenther Onkol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1923961\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:36:25Z","timestamp":1787031385000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1923961\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2026.1923961"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1923961","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"article-number":"1923961"}}